Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas
Histological identification of dispersed glioma cells in small biopsies can be challenging, especially in tumours lacking the <i>IDH1</i> R132H mutation or alterations in TP53. We postulated that immunohistochemical detection of proteins expressed preferentially in gliomas (EGFR, MEOX2,...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/15/2546 |
| _version_ | 1797586906546962432 |
|---|---|
| author | Jiri Soukup Lucie Gerykova Anjali Rachelkar Helena Hornychova Michael Christian Bartos Petr Krupa Barbora Vitovcova Zuzana Pleskacova Petra Kasparova Katerina Dvorakova Veronika Skarkova Jiri Petera |
| author_facet | Jiri Soukup Lucie Gerykova Anjali Rachelkar Helena Hornychova Michael Christian Bartos Petr Krupa Barbora Vitovcova Zuzana Pleskacova Petra Kasparova Katerina Dvorakova Veronika Skarkova Jiri Petera |
| author_sort | Jiri Soukup |
| collection | DOAJ |
| description | Histological identification of dispersed glioma cells in small biopsies can be challenging, especially in tumours lacking the <i>IDH1</i> R132H mutation or alterations in TP53. We postulated that immunohistochemical detection of proteins expressed preferentially in gliomas (EGFR, MEOX2, CD34) or during embryonal development (SOX11, INSM1) can be used to distinguish reactive gliosis from glioma. Tissue microarrays of 46 reactive glioses, 81 glioblastomas, 34 IDH1-mutant diffuse gliomas, and 23 gliomas of other types were analysed. Glial neoplasms were significantly more often (<i>p</i> < 0.001, χ<sup>2</sup>) positive for EGFR (34.1% vs. 0%), MEOX2 (49.3% vs. 2.3%), SOX11 (70.5% vs. 20.4%), and INSM1 (65.4% vs. 2.3%). In 94.3% (66/70) of the glioblastomas, the expression of at least two markers was observed, while no reactive gliosis showed coexpression of any of the proteins. Compared to IDH1-mutant tumours, glioblastomas showed significantly higher expression of EGFR, MEOX2, and CD34 and significantly lower positivity for SOX11. Non-diffuse gliomas were only rarely positive for any of the five markers tested. Our results indicate that immunohistochemical detection of EGFR, MEOX2, SOX11, and INSM1 can be useful for detection of glioblastoma cells in limited histological samples, especially when used in combination. |
| first_indexed | 2024-03-11T00:29:49Z |
| format | Article |
| id | doaj.art-d7be2a049cff41569d5bf51ef8f2b6ab |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T00:29:49Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-d7be2a049cff41569d5bf51ef8f2b6ab2023-11-18T22:46:57ZengMDPI AGDiagnostics2075-44182023-07-011315254610.3390/diagnostics13152546Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in GliomasJiri Soukup0Lucie Gerykova1Anjali Rachelkar2Helena Hornychova3Michael Christian Bartos4Petr Krupa5Barbora Vitovcova6Zuzana Pleskacova7Petra Kasparova8Katerina Dvorakova9Veronika Skarkova10Jiri Petera11Department of Pathology, Military University Hospital Prague, U Vojenske Nemocnice 1200, Praha 6, 169 02 Prague, Czech RepublicThe Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05 Hradec Kralove, Czech RepublicThe Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05 Hradec Kralove, Czech RepublicThe Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05 Hradec Kralove, Czech RepublicDepartment of Neurosurgery, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05 Hradec Kralove, Czech RepublicDepartment of Neurosurgery, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05 Hradec Kralove, Czech RepublicDepartment of Medical Biology and Genetics, Charles University, Faculty of Medicine in Hradec Králové, Zborovská 2089, 500 03 Hradec Kralove, Czech RepublicDepartment of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05 Hradec Kralove, Czech RepublicThe Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05 Hradec Kralove, Czech RepublicDepartment of Medical Biology and Genetics, Charles University, Faculty of Medicine in Hradec Králové, Zborovská 2089, 500 03 Hradec Kralove, Czech RepublicDepartment of Medical Biology and Genetics, Charles University, Faculty of Medicine in Hradec Králové, Zborovská 2089, 500 03 Hradec Kralove, Czech RepublicDepartment of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05 Hradec Kralove, Czech RepublicHistological identification of dispersed glioma cells in small biopsies can be challenging, especially in tumours lacking the <i>IDH1</i> R132H mutation or alterations in TP53. We postulated that immunohistochemical detection of proteins expressed preferentially in gliomas (EGFR, MEOX2, CD34) or during embryonal development (SOX11, INSM1) can be used to distinguish reactive gliosis from glioma. Tissue microarrays of 46 reactive glioses, 81 glioblastomas, 34 IDH1-mutant diffuse gliomas, and 23 gliomas of other types were analysed. Glial neoplasms were significantly more often (<i>p</i> < 0.001, χ<sup>2</sup>) positive for EGFR (34.1% vs. 0%), MEOX2 (49.3% vs. 2.3%), SOX11 (70.5% vs. 20.4%), and INSM1 (65.4% vs. 2.3%). In 94.3% (66/70) of the glioblastomas, the expression of at least two markers was observed, while no reactive gliosis showed coexpression of any of the proteins. Compared to IDH1-mutant tumours, glioblastomas showed significantly higher expression of EGFR, MEOX2, and CD34 and significantly lower positivity for SOX11. Non-diffuse gliomas were only rarely positive for any of the five markers tested. Our results indicate that immunohistochemical detection of EGFR, MEOX2, SOX11, and INSM1 can be useful for detection of glioblastoma cells in limited histological samples, especially when used in combination.https://www.mdpi.com/2075-4418/13/15/2546MEOX2SOX11glioblastomaEGFRINSM1CD34 |
| spellingShingle | Jiri Soukup Lucie Gerykova Anjali Rachelkar Helena Hornychova Michael Christian Bartos Petr Krupa Barbora Vitovcova Zuzana Pleskacova Petra Kasparova Katerina Dvorakova Veronika Skarkova Jiri Petera Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas Diagnostics MEOX2 SOX11 glioblastoma EGFR INSM1 CD34 |
| title | Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas |
| title_full | Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas |
| title_fullStr | Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas |
| title_full_unstemmed | Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas |
| title_short | Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas |
| title_sort | diagnostic utility of immunohistochemical detection of meox2 sox11 insm1 and egfr in gliomas |
| topic | MEOX2 SOX11 glioblastoma EGFR INSM1 CD34 |
| url | https://www.mdpi.com/2075-4418/13/15/2546 |
| work_keys_str_mv | AT jirisoukup diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT luciegerykova diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT anjalirachelkar diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT helenahornychova diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT michaelchristianbartos diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT petrkrupa diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT barboravitovcova diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT zuzanapleskacova diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT petrakasparova diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT katerinadvorakova diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT veronikaskarkova diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas AT jiripetera diagnosticutilityofimmunohistochemicaldetectionofmeox2sox11insm1andegfringliomas |